Voxelotor (Oxbryta)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

hemoglobin S polymerization inhibitor

Diseases for which it is used

History of changes in FDA indication

  • 2019-11-25: Granted accelerated approval for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older.

History of changes in EMA indication

  • 2022-02-14: Initial EMA authorization

Also known as

  • Code names: GBT-440, GTx-011
  • Brand name: Oxbryta
Retrieved from "https://hemonc.org/w/index.php?title=Voxelotor_(Oxbryta)&oldid=78108"